Brokerages Expect Keryx Biopharmaceuticals (KERX) Will Announce Quarterly Sales of $17.17 Million

Equities research analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to report $17.17 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Keryx Biopharmaceuticals’ earnings. The highest sales estimate is $17.69 million and the lowest is $16.90 million. Keryx Biopharmaceuticals reported sales of $9.53 million in the same quarter last year, which would suggest a positive year over year growth rate of 80.2%. The firm is expected to report its next earnings report on Wednesday, March 7th.

According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full year sales of $17.17 million for the current fiscal year, with estimates ranging from $58.86 million to $62.74 million. For the next fiscal year, analysts anticipate that the company will report sales of $112.69 million per share, with estimates ranging from $101.97 million to $128.27 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative net margin of 156.70% and a negative return on equity of 544.63%. The business had revenue of $15.00 million during the quarter, compared to analysts’ expectations of $18.88 million. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. The firm’s quarterly revenue was up 138.1% on a year-over-year basis.

KERX has been the subject of several research reports. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Stifel Nicolaus lowered their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Finally, ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. Keryx Biopharmaceuticals presently has a consensus rating of “Hold” and an average target price of $7.35.

A number of institutional investors and hedge funds have recently bought and sold shares of KERX. Vanguard Group Inc. lifted its holdings in Keryx Biopharmaceuticals by 5.1% during the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock valued at $52,043,000 after buying an additional 349,521 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Keryx Biopharmaceuticals by 6.9% in the 2nd quarter. Northern Trust Corp now owns 1,089,860 shares of the biopharmaceutical company’s stock valued at $7,881,000 after acquiring an additional 70,420 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Keryx Biopharmaceuticals by 1.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 973,229 shares of the biopharmaceutical company’s stock valued at $6,910,000 after acquiring an additional 10,175 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Keryx Biopharmaceuticals by 742.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 754,631 shares of the biopharmaceutical company’s stock valued at $5,358,000 after purchasing an additional 665,069 shares during the period. Finally, Monarch Partners Asset Management LLC lifted its stake in shares of Keryx Biopharmaceuticals by 62.0% in the 3rd quarter. Monarch Partners Asset Management LLC now owns 685,700 shares of the biopharmaceutical company’s stock valued at $4,868,000 after purchasing an additional 262,540 shares during the period. 64.82% of the stock is owned by institutional investors.

Keryx Biopharmaceuticals (NASDAQ KERX) traded down $0.03 during trading on Wednesday, reaching $4.59. 1,028,000 shares of the company were exchanged, compared to its average volume of 1,090,033. Keryx Biopharmaceuticals has a fifty-two week low of $4.33 and a fifty-two week high of $8.38. The stock has a market cap of $545.06, a price-to-earnings ratio of -3.06 and a beta of 4.92. The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76.

TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/10/brokerages-expect-keryx-biopharmaceuticals-kerx-will-announce-quarterly-sales-of-17-17-million.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply